New hope for rare sarcoma: targeted drug ADCE-D01 enters human trials

NCT ID NCT06797999

Recruiting now Disease control Sponsor: Adcendo ApS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new drug called ADCE-D01 in people with soft tissue sarcoma that has spread or cannot be removed by surgery. The drug is designed to find and attack cancer cells while leaving healthy cells alone. The trial will check safety, the right dose, and whether it shrinks tumors. About 270 adults who have already tried at least one other treatment may join.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC SOFT-TISSUE SARCOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC SOFT-TISSUE SARCOMA UNRESECTABLE SOFT TISSUE SARCOMA

Contacts and locations

Locations

Centre Léon Bérard
RECRUITING

Lyon, 69373, France
Memorial Sloan Kettering Cancer Center
RECRUITING

New York, New York, 10065, United States
Royal Marsden
NOT_YET_RECRUITING

London, United Kingdom
Universitair Ziekenhuis Leuven (UZ Leuven) - Campus Gasthuisberg
RECRUITING

Leuven, 3000, Belgium
University Of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States
University of Colorado Denver
RECRUITING

Aurora, Colorado, 80208, United States
University of Miami - Sylvester Comprehensive Cancer Center
RECRUITING

Miami, Florida, 33136, United States
Universitätsklinikum Essen West German Tumor Center
RECRUITING

Essen, D-45147, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.